- Home
- RPD vs BLFS Comparison
RPD vs BLFS Comparison
Compare RPD & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- BLFS
- Stock Information
- Founded
- RPD 2000
- BLFS 1987
- Country
- RPD United States
- BLFS United States
- Employees
- RPD N/A
- BLFS N/A
- Industry
- RPD Computer Software: Prepackaged Software
- BLFS Medical/Dental Instruments
- Sector
- RPD Technology
- BLFS Health Care
- Exchange
- RPD Nasdaq
- BLFS Nasdaq
- Market Cap
- RPD 1.3B
- BLFS 1.3B
- IPO Year
- RPD 2015
- BLFS 1989
- Fundamental
- Price
- RPD $19.39
- BLFS $27.74
- Analyst Decision
- RPD Hold
- BLFS Strong Buy
- Analyst Count
- RPD 19
- BLFS 7
- Target Price
- RPD $26.72
- BLFS $30.86
- AVG Volume (30 Days)
- RPD 844.9K
- BLFS 369.2K
- Earning Date
- RPD 11-04-2025
- BLFS 11-11-2025
- Dividend Yield
- RPD N/A
- BLFS N/A
- EPS Growth
- RPD N/A
- BLFS N/A
- EPS
- RPD 0.43
- BLFS N/A
- Revenue
- RPD $855,361,000.00
- BLFS $93,468,000.00
- Revenue This Year
- RPD $2.75
- BLFS $26.07
- Revenue Next Year
- RPD $3.21
- BLFS $16.86
- P/E Ratio
- RPD $44.64
- BLFS N/A
- Revenue Growth
- RPD 4.67
- BLFS 68.16
- 52 Week Low
- RPD $17.75
- BLFS $19.10
- 52 Week High
- RPD $44.48
- BLFS $29.55
- Technical
- Relative Strength Index (RSI)
- RPD 53.31
- BLFS 59.33
- Support Level
- RPD $17.84
- BLFS $26.87
- Resistance Level
- RPD $19.56
- BLFS $29.04
- Average True Range (ATR)
- RPD 0.78
- BLFS 1.00
- MACD
- RPD 0.11
- BLFS 0.07
- Stochastic Oscillator
- RPD 78.55
- BLFS 63.87
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.